News
05/08/2011
PRESS RELEASE
Vemedia Pharma continues its growth path with the acquisition of Imgroma BV in the Netherlands
17/02/2011
Press release
Vemedia Pharma performs strongly in 2010 and invests in its brands.
Download PDF
01/09/2010
Results 1st. semester 2010 & Acquisition Sleepzz
02/10/2009
PRESS RELEASE Subordinated Bonds and Subscription Rights
Private placement of Subordinated Bonds and Subscription Rights
15/05/2008
Vemedia acquires Valdispert from Solvay Pharmaceuticals and becomes a European Pharma/OTC player
Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia. To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).
27/07/2007
Acquires MethaPharma (Belgium)
16/03/2007
Subscribe for new shares
VEMEDIA PHARMA NV will issue, in cooperation with Fortis Bank, an offer to subscribe for an amount of up to EUR 15 million in New Shares with VVPR Strips and an Offer to sell 114.000 Existing Shares as of March 15, 2007.
05/08/2011
PRESS RELEASE
Vemedia Pharma continues its growth path with the acquisition of Imgroma BV in the Netherlands
17/02/2011
Press release
Vemedia Pharma performs strongly in 2010 and invests in its brands.
Download PDF
01/09/2010
Results 1st. semester 2010 & Acquisition Sleepzz
02/10/2009
PRESS RELEASE Subordinated Bonds and Subscription Rights
Private placement of Subordinated Bonds and Subscription Rights
15/05/2008
Vemedia acquires Valdispert from Solvay Pharmaceuticals and becomes a European Pharma/OTC player
Vemedia acquires Valdispert/Baldrian valerian root extract tablets, indicated in the treatment of mild to moderate sleeping disorders and states of restlessness and tension. Solvay Pharmaceuticals divests all rights to manufacture and market the products in all territories around the world to Vemedia. To finance this transaction, Vemedia Pharma will increase its capital with 4,5 million Euro, which will be subscribed by existing shareholders ( i.a. Indufin and Leeuward Ventures Sicar ), completed by mezzanine- (KBC Private Equity, Indufin ) and bank loans (Dexia, KBC bank and Rabobank).
27/07/2007
Acquires MethaPharma (Belgium)
16/03/2007
Subscribe for new shares
VEMEDIA PHARMA NV will issue, in cooperation with Fortis Bank, an offer to subscribe for an amount of up to EUR 15 million in New Shares with VVPR Strips and an Offer to sell 114.000 Existing Shares as of March 15, 2007.